Abstract： Molecular glues are small molecules that induce interactions between target proteins and regulatory proteins that would not normally interact, leading to desirable biologic or therapeutic effects. However, the rarity of serendipitous molecular glue discoveries has hindered their broader application in biological research and drug development. Over the past decade, we have identified three distinct molecular glues through phenotype-based screening and unraveled their mechanisms of action using genetic and biochemical methods. My talk will highlight our latest discovery of a molecular glue targeting multimeric protein complexes while sparing monomeric proteins. Since abnormal protein assemblies drive diseases such as autoimmunity, neurodegeneration, and cancer, our findings demonstrate the potential of multimer-selective degraders as a novel therapeutic strategy to address the root causes of these diseases.